Avid Bioservices Inc (CDMO)

[EZLibra]

You made me read up on TM-610...

"Recent studies establish a role for phosphatidylinositol-3-kinase (PI3K) and the PI3K/Akt pathway in initiation of membrane ruffling and actin stress fiber formation, events necessary for lamellipodia formation. PI3K regulates the membrane phospholipids PI(4,5)P2 and PI(3,4,5)P3 that serve pivotal roles in cell signaling, and when deregulated, contribute to tumor formation." Okay, so a cancer or virus affects PI3K's job and internal phospholipids are exposed..."And then using in vitro binding assays, we identified phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2), as the cellular target of TM-601."

My conclusion is that TM-601 is targetting exposed phospholipids, on a cellular level, which is covered in the Bavituximab patents. Thorpe has not only been granted many patents but has published an encyclopedia of prior art on this.